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Abstract
In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are
categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative
neoplasms into one subgroup independent of morphologic or prognostic features. Analyzing data of 2087 t-MDS patients
from different international MDS groups to evaluate classification and prognostication tools we found that applying the
WHO classification for p-MDS successfully predicts time to transformation and survival (both p < 0.001). The results
regarding carefully reviewed cytogenetic data, classifications, and prognostic scores confirmed that t-MDS are similarly
heterogeneous as p-MDS and therefore deserve the same careful differentiation regarding risk. As reference, these results
were compared with 4593 primary MDS (p-MDS) patients represented in the International Working Group for Prognosis in
MDS database (IWG-PM). Although a less favorable clinical outcome occurred in each t-MDS subset compared with p-
MDS subgroups, FAB and WHO-classification, IPSS-R, and WPSS-R separated t-MDS patients into differing risk groups
effectively, indicating that all established risk factors for p-MDS maintained relevance in t-MDS, with cytogenetic features
having enhanced predictive power. These data strongly argue to classify t-MDS as a separate entity distinct from other
WHO-classified t-myeloid neoplasms, which would enhance treatment decisions and facilitate the inclusion of t-MDS
patients into clinical studies.
Introduction
Therapy-related myelodysplastic syndromes (t-MDS) are
defined as MDS occurring as a complication of cytotoxic
chemotherapy and/or radiation administered for an ante-
cedent neoplastic or non-neoplastic disorder. According to
the last World Health Organization (WHO)-classification,
they belong to the group of therapy-related myeloid neo-
plasms (t-MNs) [1, 2]. From the first WHO-classification of
myeloid disorders in 2001 [3], the WHO 2008 [4], to the
current classification from 2016 [1, 2] patients with t-MDS
have been considered as having a generally poor prognosis.
From the beginning, t-MDS patients were placed toge-
ther into the large group of therapy-related myeloid neo-
plasms (t-MNs), independent of blast count and
morphologic features such as cellularity or dysplasia. In the
first WHO-classification, t-MNs were sub-classified based
on causative agents: alkylating agent/ radiation-related
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versus topoisomerase-II inhibitor-related [3]. This subdivi-
sion was removed from the next WHO-classification [4],
because in clinical practice it was difficult to apply, as many
patients received combined chemotherapeutic regimens
(alkylators, topoisomerase-II-inhibitors, antimetabolites,
antitubulin agents) and/or radiation therapy.
The 2016 WHO-classification recognizes the fact that
t-MNs can be sub-classified morphologically into t-MDS,
t-MDS/MPN, and t-AML, but considers it best to distin-
guish them collectively from p-MNs as “a unique clinical
syndrome” [1, 2], insinuating again that all t-MDS have a
uniformly poor prognosis. If this were considered true, all
treatable patients would need to receive a recommendation
for an intensive/disease-modifying treatment approach,
including allogeneic transplantation, chemotherapy, or
hypomethylating agents.
Most prognostic tools for MDS have been developed
excluding patients with t-MDS [5–7]. An exception is the
MD Anderson Prognostic Scoring System (MDAPSS) [8].
Following the categorization of t-MDS as a non-separate
subgroup of t-MN, most publications have analyzed a
conglomerate of t-MDS and t-AML, usually including both
treated and untreated patients [9–17]. Other publications
[18–20] have focused on t-AML. In contrast, publications
on t-MDS only are rare [21–23]. Not categorizing t-MDS as
a subgroup of MDS limits proper clinical decision-making,
interferes with epidemiological/ biological research, and
supports the established practice of excluding t-MDS from
clinical studies [24], thereby potentially preventing ther-
apeutic improvements.
In cooperation with centers from the International
Working Group for Prognosis in MDS (IWG-PM) as well
as the U.S. MDS Clinical Research Consortium we have
compiled a database comprising 2087 patients. After a
detailed review of all ISCN formulas, strict criteria were
applied regarding the cytogenetic data included in this
analysis. Information existed on 1245 patients for overall
survival (OS) and AML progression with complete
reviewed data to apply IPSS-R and WHO-classification. For
a comparison to primary MDS (p-MDS), we used data from
4593 patients from the IPSS-R database that was limited to
the institutions contributing data to both projects.
These two very large databases on both t- and p-MDS
enabled us to gather comparative prognostic data in t-MDS
related to p-MDS, test the performance of currently existing
tools for classification and prognostication, and finally
improve the current stratification systems for use in t-MDS.
Material and methods
Eight different study groups in the US, Germany, Spain,
Italy, Austria, and the Netherlands contributed 2087 patients
in total. By the contributing centers all patients with a
diagnosis of MDS according to WHO and/or FAB were
included if they had a history of an antecedent disease
leading to chemo- (including alkylating agents,
topoisomerase-II inhibitors, antimetabolites, and antitubulin
agents) and/or radiotherapy [1–4, 25, 26]. To test the
applicability and performance of different scoring systems
as well as classifications strict inclusion/exclusion criteria
were applied. Selection criteria included information about
primary disease, pretreatment (at least chemotherapy or
radiation), valid data to calculate the IPSS-R, survival data,
AML transformation, valid stratification variables age, sex,
and year of diagnosis. Patients were excluded if age <16
years, AML-defining cytogenetic abnormalities [inv(16),
t(15;17), t(8;21)], peripheral blasts >19%, normal kar-
yotypes based on <10 metaphases analyzed, proliferative
CMML, AML as a primary diagnosis, survival or time to
AML < 2 months occurred, and if the primary disease was
in progression, to focus on the prognostic impact of the
MDS itself. Karyotype was documented within the ISCN
formula [27] after cytogenetic review (performed by DH,
FS, JG, and BH). Treatment in MDS-phase, including
intensive AML-type chemotherapy and allogeneic stem cell
transplantation, was not an exclusion criterion, but the
analyses were repeated with untreated patients only. These
results are given in the supplement.
FAB, WHO-2016, IPSS-R, and WPSS-R classifications
were calculated. For the WHO-classification RCUD,
RARS, and MDS del(5q) were grouped together as in the
WPSS. To test and quantify differentiating abilities of these
tools the stratified log-rank test and the stratified Dxy-
coefficient [28] were applied. Dxy is a concordance coef-
ficient varying between −1 and 1, with 0 representing no
monotone discriminative ability and 1 perfect monotone
discrimination of a tool with respect to the time of interest
(transformation free survival, overall survival, time to
AML). As the main risk criterion, we used transformation-
free survival since as a combined endpoint it described the
clinically relevant disease-related risk more appropriately
than overall survival. For completeness, Dxy values for
overall survival and time to AML transformation were also
included. In detail, time variables were defined as follows:
all start with diagnosis of MDS and are censored, if no
event occurred until the end of follow up. Transformation
free survival ends when transformation or death without
transformation occur. Time to AML ends with transforma-
tion but is censored in case of death without transformation.
The results are based on stratified analyses compensating
for possible confounding influences of sex, age, center, and
year of diagnosis. Except for the influence of the primary
diagnosis on the outcomes analyzed, we also stratified for
primary diagnosis. Event time was calculated from time of
MDS-diagnosis. Time to AML transformation was analyzed
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by censoring at time of death and in addition by treating
death as competing event. Cumulative incidence curves for
death with and without transformation are shown in the
supplement.
All analyses were conducted with the statistics software
R 3.4.3, including the package “survival” [29, 30]. Two-
sided P values less than 0.05 were considered significant. In
line with the essentially exploratory nature of the study, no
adjustment for multiple testing was applied.
Data from t-MDS patients were compared with a cohort
of 4593 untreated p-MDS patients from six different study
groups within the IPSS-R database, including only patients




Of the total number of 2087 t-MDS patients, 1245 fulfilled
all relevant selection criteria. Patients with high-risk (22%)
and very high-risk (31%) IPSS-R score were more frequent
among t-MDS than in the p-MDS group. Although less
frequent, a considerable number (8% and 21% patients) had
an IPSS-R of very low and low-risk, respectively (p <
0.001). Concordantly, as expected from previous publica-
tions [8], 30% t-MDS patients had a very poor and 15% a
poor-risk cytogenetic score, and 27% had ≥5 abnormalities.
Conversely, 2% and 37% patients were diagnosed with a
very good or good-risk karyotype, respectively: 30% pre-
sented with a normal karyotype and 21% with only a single
aberration. Patient characteristics as well as a comparison to
p-MDS can be found in Table 1 and Supplementary Table 1
(the same analysis, limited to untreated patients is shown in
Supplementary Table 2). Regarding WHO, the size of the
four different risk groups was almost equal: RCUD, RARS,
and MDS del(5q) 25%, RCMD 32%, RAEB-1 23%, and
RAEB-2 21% and the distribution of the sub-groups were
relatively similar to p-MDS (34%, 29%, 17%, and 20%).
However, patients with RAEB-I were more frequent and
RARS (6 vs. 13%), MDS del(5q) (1 vs. 4%), as well as
MDS/MPN (CMML, excluding proliferative CMML) (4 vs.
10%) were less frequent (p < 0.001). The median overall
survival was 18 months with a median follow up of
60 months for the t-MDS patients. The group of untreated
p-MDS patients from the IPSS-R database had a median
survival of 41 months. Median follow up was 49 months for
this cohort, respectively.
The t-MDS patients’ primary diagnoses were a solid
tumor in 54% and a hematological disease in 43%. The
remaining 13% of patients had received treatment for a
benign immunological disease. Treatment included
Table 1 Patient characteristics of therapy-related (t-MDS) and primary
(p-MDS) myelodysplastic syndromes (additional information on
patient characteristics regarding participating centers and year of
diagnosis and a comparison of untreated patients only is shown in








n % n %
MDS treatment
Treateda 715 63% 0 0%
Untreated 422 37% 4593 100%
Total with information 1137 91% 4593 100%
Stem cell transplantation
Yes 210 19% 0 0%
No 906 81% 4593 100%
Total 1116 90% 4593
Age (years) <0.001
≤60 342 28% 1053 23%
>60 to ≤70 395 32% 1267 27%
>70 to ≤80 404 32% 1601 35%
>80 104 8% 672 15%
Median 68 70
Total 1245 100% 4593 100%
Gender <0.001
Male 680 55% 2854 62%
Female 565 45% 1739 38%
Total 1245 100% 4593 100%
FAB <0.001
RA 490 40% 1707 37%
RARS 110 9% 839 18%
RAEB 455 38% 1217 27%
RAEB-T 81 7% 328 7%
CMML 44 4% 435 9%
Unclassified 29 2% 67 2%
Total 1209 97% 4593 100%
WHO <0.001
RCUD 183 17% 639 17%
RARS 66 6% 507 13%
RCMD 335 31% 1097 29%
RAEB-1 246 22% 627 16%
RAEB-2 219 20% 748 19%
MDS (del5q) 13 1% 143 4%
MDS-U 29 3% 90 2%
Total 1091 88% 3851 84%
IPSS-R <0.001
Very low 105 8% 893 19%
Low 260 21% 1644 36%
Intermediate 225 18% 882 19%
High 275 22% 628 14%
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chemotherapy only in 46%, radiation only in 19%, and both
in 35% of the patients.
Application of classification and prognostic scoring
systems
All classification and prognostic scoring systems applied
were able to discriminate different risk groups within our
t-MDS cohort, although the performance of the scoring
systems was inferior when compared with p-MDS. The
prognostic power measured by Dxy for the different clas-
sification and scoring systems in t- and p-MDS is given in
Table 2 (the same analysis, limited to untreated patients
only, is shown in Supplementary Table 3). The FAB-
classification (Supplementary Fig. 1a) could only dis-
criminate two different adjacent risk groups (RA vs. RAEB
p < 0.001). There was no significant prognostic difference
between RA and RARS (p= 0.8) as well as RAEB and
RAEB-T (p= 0.291). However, these results are in line
with results obtained in primary MDS and are thus not
t-MDS specific. To examine the WHO-classification, we
decided to use the categorization used within the WPSS, as









n % n %
Very high 380 31% 546 12%
Total 1245 100% 4593 100%
WPSS-R <0.001
Very low 83 8% 822 22%
Low 164 15% 1036 28%
Intermediate 228 21% 654 17%
High 399 38% 916 24%
Very high 188 18% 325 9%




Very good 24 2% 150 3%
Good 460 37% 3261 71%
Intermediate 198 16% 622 14%
Poor 184 15% 197 4%
Very poor 379 30% 363 8%




0 377 30% 2753 73%
1 266 21% 706 19%
2 144 12% 136 4%
3 77 6% 55 2%
4 50 4% 28 1%
≥5 331 27% 76 2%





Other solid tumor 342 28%
Non-malignant disease 43 3%
Total 1242 99,8%
Years from primary diagnosis to MDS
Median (years) 6.9
≤2 130 11%
>2 to ≤4 216 18%
>4 to ≤8 347 29%
>8 to ≤16 356 29%
>16 166 14%
Total 1215 98%
Therapy for primary disease












n % n %
Radiation alone 243 19%
Radioactive iodine 11 1%
Chemotherapy alone 568 45%


















aHMAs, chemotherapy, and/or allogeneic HSC transplant.
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RCUD, RARS, and MDS (del5q). With this combined low-
risk group a better separation versus the remaining cate-
gories could be achieved, although there was no statistical
significant difference between MDS with unilineage dys-
plasia (RCUD plus RARS plus MDS(del5q)) and MDS
with multilineage dysplasia (p= 0.389), while RCMD vs.
RAEB I (p < 0.001) and RAEB I vs RAEB II (p < 0.001)
differed significantly (Fig. 1a). The same observation could
be made in p-MDS (RCUD, RARS+MDS(del5q) vs.
RCMD p= 0.403; RCMD vs. RAEB I p < 0.001; RAEB I
vs RAEB II p < 0.001).
The two prognostic scoring systems performed both very
well. The IPSS-R could separate five different risk groups
for all outcomes tested (Fig. 1b), while the WPSS separated
five risk groups regarding OS, but only four regarding PFS
and AML transformation (see Supplementary Fig. 1b). The
influence of IPSSR(A) is shown in Supplementary Fig. 1c.
Regarding these outcomes, the difference did not reach
statistical significance between low and very low-risk,
likely because the very low-risk group was relatively small
(p= 0.146).
When we analyzed the performance of the cytogenetic
component of the IPSS-R (cipssr), the prognostic power
was already very high on its own. Only the difference
between the very low and low-risk group did not reach
statistical significance (p= 0.210), but this might very
likely be a matter of the size of the very low-risk group (n
= 24). The performance of the cipssr was at least equal in t-
MDS compared with p-MDS (Fig. 1c).
Other possible, t-MDS specific influences like the pri-
mary diagnosis (Dxy 0.05) or type of prior treatment did
not influence the different outcomes significantly. Only
patients with other, non-malignant disease appeared to have
a better outcome (Supplementary Fig. 1d, p= 0.051).
Cumulative incidence of death with and without transfor-
mation as an addition to Fig. 1a–c are shown in Supple-
mentary Fig. 2a–c.
Since the prognostic values of all classification and
scoring systems as well as single variables, except the
cipssr, were inferior compared with p-MDS (Dxy (IPSS-R)
in t-MDS 0.38 for OS and 0.35 for time to AML), we
analyzed if this was influenced by the fact that our cohort
was a mixture of treated and untreated patients. This
hypothesis could be verified since all scoring systems per-
formed much better in the subsample of untreated t-MDS
patients (see Fig. 2a–c and Supplementary Fig. 3a–c). In
this subgroup the Dxy for the IPSS-R was not inferior (0.45
for OS and 0.48 for time to AML) when compared with the
p-MDS cohort (0.40 for OS and 0.53 for time to AML) and
for the cipssr 0.30 and 0.54 in t-MDS versus 0.23 and 0.28
in p-MDS (Supplementary Table 3).
Although patients with t-MDS in general could be clas-
sified by the WHO-classification system developed for
p-MDS, its performance differed within specific t-MDS
subgroups. The prognostic power was almost comparable to
p-MDS in patients with a solid tumor as primary disease as
well as in patients after radiotherapy only. In patients with a
history of a hematologic disease or after chemotherapy, the
prognostic power was lower. However, even in these sub-
groups, patients with different outcomes could be separated
(see Fig. 3a–c and Supplementary Fig. 4a–c).
Discussion
In this collaborative IWG-PM project, we were able to
assemble the largest database on t-MDS to date, offering the
analysis of well-characterized and clinically annotated data
with a long follow up. Our analyses of the data presented
here showed that patients with t-MDS benefited in a major
way from receiving differentiated classification and prog-
nostic evaluation, distinct from t-MN. Our scrupulous
evaluation of the patients’ earlier treatment for malignant or
non-malignant disease contributed to our case-finding.
T-MDS has been relatively neglected regarding classifi-
cation and differentiated prognostication. All versions of the
WHO-classification, including the latest from 2016, do not
classify t-MDS within the group of MDS [1, 2]. Instead,
t-MDS patients are currently still placed together with t-
AML and t-MPD in a combined category of therapy-related
myeloid neoplasms [1, 2]. Moreover, most established
scoring systems were developed excluding t-MDS patients.
The only t-MDS specific score was published by Quintas-
Cardama et al. including variables such as performance
status and age, which determine patient-related but not
Table 2 Dxys for the different scoring systems and outcomes
presented for t- and p-MDS (therapy-related and primary
myelodysplastic syndromes): FAB (French-American-British
classification), WHO (World Health Organization classification),
IPSS-R (International Prognostic Scoring System-revised), WPSS-R
(WHO-based Prognostic Scoring System-revised, cipssr (cytogenetic




Overall survival Time to AML
t-MDS p-MDS t-MDS p-MDS t-MDS p-MDS
FAB 0.19 0.30 0.17 0.28 0.24 0.42
WHO 0.24 0.29 0.19 0.26 0.41 0.44
IPSS-R 0.37 0.41 0.38 0.40 0.36 0.53
WPSS-R 0.35 0.38 0.33 0.36 0.40 0.51
cipssr 0.30 0.23 0.32 0.23 0.23 0.28
Number of
aberrations
0.29 0.13 0.32 0.13 0.22 0.14
Primary
diagnosis
0.05 / 0.05 / 0.03 /
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disease-specific risk features, and performance status might
not be readily available in all databases [23].
Until now, only one paper analyzed the impact of the
WHO-classification for p-MDS in t-MDS [21]. This pub-
lication by Singh et al. [21] included 155 patients with
t-MDS or t-AML of whom only 81 patients were t-MDS.
No differences were found in median survival times among
patients classified into the different WHO subgroups and
Singh and coworkers described a uniformly poor outcome
in t-MDS regardless of morphologic classification. These
results might be explained partially by the difference in size
compared with our patient cohort. Furthermore, the paper
includes patients not in remission from their primary dis-
ease. We excluded such patients to obtain a cleaner esti-
mation of the specific MDS-related risk.
Earlier publications on t-MDS demonstrated mostly
high-risk karyotypes in these patients, mainly including
chromosome 5 and 7 abnormalities as well as complex
karyotypes, in more than 90% of patients [9, 31, 32].
Although these features are still a hallmark of t-MDS in
Fig. 1 Outcome of patients with t-MDS according to different tools for classification and prognosis. a outcome according to WHO 2016,
b outcome according to IPSS-R, c Outcome according to cytogenetic IPSS-R risk categories.
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general, they do not represent all patients with a history of
chemo- and/or radiotherapy. Our data demonstrated an
unexpectedly high percentage of good-risk and normal
cytogenetics, which are concordant with other
more recently published data [13, 19, 23]. Regarding these
early t-MDS publications, a reporting bias may have con-
tributed since in some cases conspicuous cytogenetics
might have been required for the question about previous
treatments.
Even in the most recent WHO-classification [1, 2] the
prognosis of t-MN is described as being generally poor and
that prognosis of these patients is influenced strongly by
karyotype as well as by the primary disease. Although this
important information is given in the Revised Fourth Edi-
tion of the WHO series on histological and genetic typing of
human tumors it remains purely descriptive, as it provides
no consequences for the resulting t-MN classification.
Chromosome 5 and/or 7 abnormalities, TP53 mutations,
Fig. 2 Outcome of patients with t-MDS according WHO-classification depending on treatment in MDS phase and comparison to p-MDS.
a Outcome according to WHO-classification for treated patients. b Outcome according to WHO-classification for untreated patients. c Outcome
according to WHO: p-MDS.
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and complex karyotype are indicated by the WHO as hav-
ing a particularly poor outcome, while patients with
balanced translocations were stated to have a good prog-
nosis, albeit not as good as in p-MN. However, exceptions
to these generalizations are notable. In our database we
observed some patients with isolated del(5q) and a history
of exposure to mutagenic agents that have a good prognosis,
as is the case in p-MDS [33]. Conversely, considered
typical for t-MDS is the group with balanced translocations
involving chromosome band 11q23, the localization of the
MLL/KMT2A-gene [9, 33–37]. These translocations can, in
contrast to the typical good risk “AML defining transloca-
tions” t(8;21), t(15;17), and inv(16), occur as t-MDS and are
associated with an extremely poor prognosis as previously
described [9, 33–37]. These categorization problems relate
in part from combining t-MDS and t-AML leading to
the use of AML cytogenetic classification systems for the
entire group of t-MN. In our study we have demonstrated
Fig. 3 Outcome of patients with t-MDS according WHO-classification depending on the primary disease and comparison to p-MDS.
a Outcome according to WHO: primary disease hematologic. b Outcome according to WHO: primary disease solid tumor c Outcome according to
WHO: p-MDS.
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that the influence of cytogenetics is very high in t-MDS and
the prognostic power of the cipssr is in t-MDS at least as
good as in p-MDS, due to a high proportion of abnormal
karyotypes. Without a proper morphological classification
and separation from t-AML, t-MDS patients are also with-
held the most powerful tool for prognostic evaluation.
In addition, prognostic factors for t-MDS, other than
cytogenetics, are not recognized by the WHO-classification.
In practice, this means that a patient with a blast count of
0% (t-MDS) is in the same risk category as a patient with a
blast count of 99% (t-AML). Also, with the current WHO-
classification irrelevant for therapeutic decision-making is
whether a patient has dysplastic (t-MDS) or proliferative
disease (t-MDS/MPD). These issues have major implica-
tions for patient therapy. Thus, proper morphologic and
cytogenetic classification as well as separation from t-AML,
provide t-MDS patients a most powerful method for treat-
ment considerations.
Our data demonstrated that t-MDS patients can be sub-
divided by diagnostic procedures into groups with clearly
varying prognoses. These findings are underlined by results
from smaller group analyses focusing on the value of
prognostic scoring systems [22, 23, 38]. It should be con-
sidered in particular that sporadic MDS cases might be
assigned to the group of t-MN based on their therapeutic
history although this could be only coincidental, and they
actually belong to p-MDS. Observational data on MDS
patients cannot prove a causal link between therapy and a
later developing MDS. This fact is already implied by the
term “therapy-related”. As we cannot differentiate
between the two situations this should not be taken as an
argument for a less scrupulous diagnostic classification of
the concerned patients. Quite the contrary, such
spontaneously developed MDS within the t-MDS group
have the greatest disadvantage from not being classified as
p-MDS.
In addition, we note that the survival of t-MDS patients
in different WHO groups was inferior to p-MDS, similar
to findings in t- vs p-AML [18, 19]. This might have
several reasons, including patient-related factors asso-
ciated with the primary disease (relapse/progression of the
primary disease, cumulative toxicity of primary and sec-
ondary therapy on bone marrow reserve as well as other
organ function), as previously discussed
[10, 19, 22, 39, 40]. A second point for discussion might
be the retrospective nature of our, as well as previous
studies. And third, in the present database, we can only
compare data from a t-MDS group that is heterogeneous
regarding treatment to an untreated group of p-MDS
patients. As we have demonstrated, this influences the
power of prognostic models and likewise will influence
patient outcomes in general as well, although further
analyses are needed to understand the exact nature of such
effects. We find a relevant shift towards better risk
patients in our t-MDS cohort if we look at untreated
patients only. It is likely, that there will be a similar shift
in the p-MDS cohort as well, since treated p-MDS patients
were not included in our reference database (compare
Figs. 4 and 5). Results in t- and p-MDS would possibly be
better comparable if the analysis were restricted to
untreated patients only. However, regarding the main
issue of differentiating and sub-classifying tMDS exclu-
sion of treated cases would bias those conclusions, since
we observed a relevant shift towards older age and lower-
risk disease among untreated patients (Fig. 5, Supple-
mentary Table 2).
Further, in addition to patient and method-related factors,
biological differences between the leukemic stem cells
might contribute as well, since inferior outcome of patients
with t-MDS seems not only limited to survival. Especially
in the good and intermediate-risk group, we observe this
phenomenon with regard to AML transformation (see
Fig. 6a–c and Supplementary Fig 5a-c). It is possible that,
even within each subgroup there is a shift to higher risk
cytogenetic or molecular abnormalities. This will be an
important comparison for future analyzes. The impact of
cytogenetics appears to be even greater in t-MDS compared
with p-MDS. The major reason might be that the proportion
of patients with aberrant karyotype was higher in t-MDS. In
p-MDS, about half of the patients presented with a normal
karyotype and 71% belonged to the large cipssr good risk
group, whereas in t-MDS it was only 30 and 37%,
respectively (see Table 1).
Regarding molecular differences, Singhal et al. found
that t-MDS patients with ≥15% ringed sideroblasts had a
low frequency of SF3B1 mutations, but a much higher
frequency of TP53 mutations compared with patients with
p-MDS [41]. In line with this observation the same analysis
showed a generally much higher frequency of TP53 muta-
tions in patients with t-MDS and about half of the patients
had <5% marrow blasts at the time of t-MDS diagnosis
[41]. Clonal hematopoiesis or germline predisposition can
be found in hematopoietic cells of patients who develop
t-MN, even before treatment of the prior disease, repre-
senting a sign of increased chromosomal instability and
high-risk disease [16, 41–44]. However, preceding clonal
hematopoiesis or genetic predisposition can also be found
before the development of p-MDS [45–49].
Pedersen-Bjergaard et al. [50] suggested 25 years ago
different genetic pathways for t-MDS and t-AML due to
their differing distribution of genetic abnormalities. While
this is the case for some t-MNs, in other cases, as has been
evident with more recently developed mutational data, a
biological continuum exists from clonal hematopoiesis to
t-MDS and “secondary” t-AML with or without a MDS pre-
phase and MDS-related features [16, 20, 41, 42]. These
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different mechanisms of leukemogenesis occur in therapy-
related as in primary MNs.
Our data showed that, transformation-free survival (TFS)
was poorer in t-MDS subgroups vs those in p-MDS: range
8–22 months, compared with 13–63 months, respectively. The
impact of blast count and the performance of morphological
classifications in t-MDS was somewhat less than in p-MDS,
but remained substantial, in contrast to earlier, smaller pub-
lications [21]. Thus, all patients can and should be subdivided
into different diagnostic subcategories and risk groups.
Knowledge of the diagnostic and prognostic evaluation
of t-MN patients according to pathogenesis and disease
characteristics is required for selecting patients who can
be cured or will at least benefit from active treatment
[10, 24] and would facilitate clinical as well as epide-
miological research. An updated classification should
separate t-MDS from t-AML and t-MDS/MPN as
although these diseases might share some overlapping
features, they exhibit differences in clinical presentation
and molecular and cytogenetic characteristics [51, 52]. As
Fig. 4 Distribution of risk
groups according to different
classification and prognostic
tools for p- versus t-MDS.
a Distribution of IPSS-R
subgroups in p- and t-MDS.
b Distribution of WHO-
subtypes (according to WPSS+
RAEB-T) in p- and t-MDS.
c Distribution of cytogenetic
IPSS-R subgroups in p- and
t-MDS. d Distribution of
number of aberrations in
p- and t-MDS.
Fig. 5 Distribution of risk groups according to different classifi-
cation and prognostic tools for treated versus untreated patients.
a Comparison of IPSS-R risk-groups between treated and untreated
patients. b Comparison of IPSS-R cytogenetic risk-groups between
treated and untreated patients. c Comparison of WHO subgroups
between treated and untreated patients.
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for t-MDS, the feasibility of further sub-classification has
been demonstrated by publications on t-AML as well
[9, 18, 19, 37, 53–56]. Regarding t-MDS/MPN, only 4%
of the patients in our database presented with t-CMML
dysplastic, as its frequency is lower in t- compared with
p-MDS [57]. Patients with t-CMML proliferative were
excluded from this analysis. Our data indicate for all
t-MDS an increased influence of karyotype on prognosis
compared with other prognostic variables. This finding is
similar to that demonstrated for p-CMML and t-CMML
wherein the frequency of cytogenetic abnormalities is
much higher in t-CMML, while the frequency of most
molecular abnormalities seems to be comparable [57].
Based on this important publication, Patnaik et al. suggest
that, due to the unique biological pattern and dismal
prognostic impact, t-CMML should be considered as
separate subtype in the classification scheme for both
CMML and t-MN [57].
Based on our findings, we believe this newly established
disease category t-MDS deserves further p-MDS-like sub-
categorization. We propose an approach using the WHO
classification for p-MDS, but preceding each subgroup with
a t-; for example, t-MDS-SLD, t-MDS-MLD, etc. We
suggest restricting the use of prognostic systems to t-MDS
patients in remission from their primary disease so as not to
confound the results of risk factors for the MDS. For those
not in remission it would be important to incorporate the
confounding risk of the primary disease into clinical
decision-making.
In summary, our data demonstrated that classification
tools established in p-MDS were effective for stratifying
subgroups in t-MDS and indicated the high prognostic
relevance of cytogenetics in t-MDS. These findings from
the largest t-MDS database to date should initiate a dis-
cussion of a potential revision of the WHO-classification
and encourage clinicians to use the existing tools for risk
Fig. 6 Comparison of outcome according to different tools for classification or prognostic evaluation t- versus p-MDS. a Comparison p- and
t-MDS according to WHO-classification. b Comparison t- and p-MDS according to IPSS-R risk-categories. c Comparison t- and p-MDS according
to cytogenetic IPSS-R categories.
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assessment and treatment decisions for patients with
therapy-related disease.
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